Association of T cell changes with C-peptide preservation
We designated post hoc clinical responders as participants who lost ≤9.7% of their baseline C-peptide at month 6 based on published criteria and examined a correlation with immunological results. Seven of 16 (44%) participants (5/9 adults and 2/7 adolescents) in the AG019 monotherapy group were classified as responders at 6 months. In AG019/teplizumab combination therapy, there were 11/14 (79%) responders (7/10 adults and 4/4 adolescents) at month 6 and 0/3 in the placebo group (ESM Table PPI-specific CD8